News

One of the biggest current areas of research is precision medicine, which will transform patient care for generations to come. Here's how one hospital is applying it.

Patients with chronic diseases who received a home visit in HealthPartners’ pilot MTM program reduced readmissions within the first year. Find out how.

A new report found that the majority of state Medicaid programs cannot afford hepatitis C medications, such as Harvoni and Sovaldi (Gilead Sciences), which can cost nearly $100,000 for a single course of treatment.

In another win for biosimilar drugs, FDA staff recently decided that Celltrion and Pfizer’s biosimilar (Remsima) to Johnson & Johnson’s Remicade for rheumatoid arthritis was “highly similar” to the branded drug.

It’s tough for managed care executives to keep up with clinical research, evidence, and studies on an ongoing basis. Here are some tips.

The telemedicine changes we have seen so far are nothing compared to what we’re likely to see in 2016.

Twenty American corporations join to improve the way employee healthcare benefits will be purchased in an effort to create better outcomes.

FDA has approved expanded use of daclatasvir (Daklinza, Bristol-Myers Squibb) in combination with Gilead Sciences' Sovaldi (sofosbuvir), for the treatment of patients with chronic hepatitis C (HCV) genotype 1 or 3.

In one of the few arrangements of its kind, Cigna Corp and Aetna Inc. struck a deal with Novartis for a performance-based price for its heart failure drug, Entresto.

The Zika virus, a mosquito-borne epidemic in Brazil that is causing birth defects, was recently reported in the U.S. Here are the top 5 things to know about the disease:

After receiving pressure from Congress, FDA announced several measures aimed at curbing opioid abuse. The new plan calls for increasing abuse-deterrent formulations of opioid medications and upping access to naloxone and alternative pain treatments.

Mercy Accountable Care Organization (ACO) has identified and successfully leveraged a critical factor to supplement its population health strategies.

PhRMA ad campaign features new patient and researcher stories.

Industry watchers weigh in following Covered California’s Peter Lee’s public bashing of UnitedHealth over the federal exchanges.

Much of the drug pricing debate in the United States in recent months has centered around the soaring prices of hepatitis C medications such as Harvoni and Sovaldi (Gilead Sciences), along with Technivie and Viekira Pak (AbbVie). However, the newly approved hepatitis C drug, Zepatier (elbasvir and grazoprevir, Merck) ups the pricing competition.

PBMs, insurers use cautious approach when managing these cholesterol-lowering drugs.

FDA has approved amphetamine extended-release orally disintegrating tablet (Adzenys XR-ODT, Neos Therapeutics, Inc.) for the treatment of ADHD in patients 6 years and older.

FDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with metastatic melanoma.

Drug price increases can prove challenging for payers. Here’s six strategies to keep in your arsenal.

Humana is using past evidence to reach patients at risk for diabetes.

How at-risk negotiations with pharmaceutical manufacturers and medication adherence programs improve both sides of the healthcare value equation: patient outcomes and costs.

Over the past year, there has been some legislative movement at the federal and state levels. The following is a short list of key bills and what they might mean for healthcare providers.

As 2016 gets underway, improvements in diabetes health management are expected to progress. Here are some of the noteworthy trends to watch.

How did the ICD-10 transition impact health systems and health plans? Here, those in the field, weigh in.

Johnson & Johnson faces $800 million racketeering lawsuit over its antibiotic, Levaquin.

Tresiba, the long-acting insulin that just came on the market in January, stands to net Novo Nordisk billions of dollars.

FDA recently approved (Halaven, Eisai), the first chemotherapy drug to demonstrate survival benefit for liposarcoma that cannot be removed by surgery or is advanced.

Rule would expand standards health plans must meet to be certified as qualified health plans